×
  • Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Slip Disc Market Trends

    ID: MRFR/MED/2785-CR
    108 Pages
    Rahul Gotadki
    August 2017

    Slip Disc Market information, by types (thoracic herniated discs, lumbar herniated disc, and others), by diagnosis (physical examination, nerve conduction test, and others), by treatment (medications, therapy, and others) - global forecast till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Slip Disc Market Infographic
    Purchase Options

    Market Trends

    Key Emerging Trends in the Slip Disc Market

    The term "spinal injury" encompasses damages inflicted upon the spinal cord, arising from trauma, diseases, or degeneration. Individuals with spinal cord injuries (SCIs) face a significantly heightened risk of premature death, ranging from 2 to 5 times more than those without such injuries. The severity of this condition is exacerbated in low and middle-income countries, where survival rates are notably grim. Factors contributing to this disparity include limited income, inadequate technological resources, a lack of awareness regarding available treatments, and challenging reimbursement scenarios.

    According to iMedPub, in 2016, the estimated global annual incidence of spinal injuries was projected to be between 40 to 80 individuals per million population worldwide. Alarmingly, these injuries exhibit disproportionately poor survival rates in economically disadvantaged countries. The overwhelming majority, up to 90%, of these cases are attributed to traumatic causes. However, there is a foreseen shift in the landscape, with an expected rise in non-traumatic spinal cord injuries in the future.

    Adding to the gravity of the situation, global statistics reveal that each year witnesses approximately 250,000 to 500,000 individuals grappling with spinal cord injuries. Astonishingly, a significant proportion of these cases are preventable, stemming from causes such as accidents, violence, and falls. This underscores the urgent need for enhanced preventive measures and increased awareness to mitigate the incidence of spinal injuries globally.

    The multifaceted challenges associated with spinal injuries extend beyond the physical toll on affected individuals. The socioeconomic ramifications are profound, especially in regions with limited resources and accessibility to advanced medical technologies. The dire survival rates underscore the critical importance of addressing the root causes of spinal injuries, with a focus on both traumatic and non-traumatic factors.

    Efforts to mitigate the impact of spinal injuries must encompass a comprehensive approach. This includes raising awareness about preventive measures, fostering advancements in technology and medical infrastructure, and advocating for improved reimbursement systems. Additionally, bridging the gap in knowledge about available treatments is crucial for enhancing the prognosis and quality of life for those affected by spinal injuries.

    In conclusion, the escalating prevalence of spinal injuries globally poses a significant public health concern. The stark contrast in survival rates between high and low-income countries highlights the urgent need for targeted interventions to address the root causes, enhance preventive measures, and improve the overall management of spinal injuries. A concerted effort on a global scale is imperative to mitigate the impact of spinal injuries and improve the outcomes for affected individuals.

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    Market Summary

    As per MRFR analysis, the Slip Disc Market Size was estimated at 9.2 USD Billion in 2024. The Slip Disc industry is projected to grow from 9.941 USD Billion in 2025 to 21.56 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 8.05 during the forecast period 2025 - 2035.

    Key Market Trends & Highlights

    The Slip Disc Market is experiencing notable growth driven by technological advancements and increasing awareness of spinal health.

    • North America remains the largest market for slip disc treatments, reflecting a robust healthcare infrastructure.
    • The Asia-Pacific region is emerging as the fastest-growing market, driven by rising healthcare expenditures and population awareness.
    • Surgical interventions dominate the market, while therapy-based treatments are rapidly gaining traction due to their non-invasive nature.
    • The rising incidence of back disorders and advancements in medical technology are key drivers propelling market growth.

    Market Size & Forecast

    2024 Market Size 9.2 (USD Billion)
    2035 Market Size 21.56 (USD Billion)
    CAGR (2025 - 2035) 8.05%
    Largest Regional Market Share in 2024 Asia Pacific

    Major Players

    <p>Medtronic (US), Johnson & Johnson (US), Stryker (US), NuVasive (US), DePuy Synthes (US), Globus Medical (US), B. Braun Melsungen AG (DE), Zimmer Biomet (US), Orthofix Medical Inc. (US)</p>

    Market Trends

    The Slip Disc Market is currently experiencing a notable evolution, driven by a combination of technological advancements and an increasing awareness of spinal health. As healthcare providers and patients alike become more informed about the implications of spinal disorders, there appears to be a growing demand for innovative treatment options. This shift is likely influenced by the rising prevalence of conditions associated with disc herniation, which may lead to heightened interest in both surgical and non-surgical interventions. Furthermore, the integration of minimally invasive techniques into treatment protocols seems to enhance patient outcomes, thereby fostering a more favorable environment for market growth. In addition to technological progress, the Slip Disc Market is also shaped by demographic factors. An aging population, coupled with lifestyle changes that contribute to musculoskeletal disorders, indicates a potential increase in the number of individuals seeking treatment for slip discs. This demographic shift may prompt healthcare systems to adapt their approaches, focusing on preventive measures and early intervention strategies. As the market continues to evolve, stakeholders must remain vigilant in monitoring these trends to effectively address the needs of patients and healthcare providers alike.

    Technological Advancements in Treatment

    The Slip Disc Market is witnessing a surge in the adoption of advanced treatment modalities. Innovations such as robotic-assisted surgeries and enhanced imaging techniques are transforming traditional approaches, potentially leading to improved surgical precision and patient recovery times. This trend suggests a shift towards more effective and less invasive options, which may appeal to a broader patient demographic.

    Increased Awareness of Spinal Health

    There is a growing recognition of the importance of spinal health among both healthcare professionals and the general public. Educational campaigns and resources are likely contributing to this heightened awareness, which may result in more individuals seeking timely interventions for slip disc conditions. This trend indicates a proactive approach to managing spinal disorders.

    Demographic Shifts and Lifestyle Changes

    The Slip Disc Market is influenced by demographic changes, particularly the aging population and evolving lifestyle habits. As more individuals engage in sedentary activities and experience age-related degeneration, the demand for slip disc treatments may increase. This trend highlights the need for healthcare systems to adapt their strategies to address the unique challenges posed by these demographic factors.

    Slip Disc Market Market Drivers

    Increased Healthcare Expenditure

    The rise in healthcare expenditure across various regions is a notable driver of the Slip Disc Market. As governments and private sectors allocate more resources to healthcare, there is a corresponding increase in funding for spinal health initiatives and treatments. This trend is particularly evident in countries with aging populations, where the demand for effective slip disc treatments is surging. Data indicates that healthcare spending is projected to grow at an annual rate of approximately 7 percent, which is likely to enhance access to advanced treatment options for patients suffering from slip disc conditions. Furthermore, increased investment in research and development is expected to yield innovative therapies and technologies, thereby expanding the market landscape. As healthcare systems evolve, the focus on improving patient outcomes and reducing the economic burden of spinal disorders will continue to drive growth in the Slip Disc Market.

    Advancements in Medical Technology

    Technological innovations in medical devices and treatment methodologies are significantly influencing the Slip Disc Market. The introduction of cutting-edge imaging techniques, such as MRI and CT scans, has enhanced diagnostic accuracy, enabling healthcare professionals to identify slip disc conditions more effectively. Furthermore, advancements in surgical techniques, including endoscopic procedures and robotic-assisted surgeries, have improved patient outcomes and reduced recovery times. Data indicates that the market for spinal surgery devices is projected to grow at a compound annual growth rate of over 5 percent in the coming years. These technological advancements not only facilitate better treatment options but also foster patient confidence in seeking medical intervention for slip disc issues. As the industry continues to evolve, the integration of artificial intelligence and telemedicine may further transform the landscape, making treatments more accessible and efficient for patients worldwide.

    Rising Incidence of Back Disorders

    The increasing prevalence of back disorders, particularly among the aging population, appears to be a primary driver of the Slip Disc Market. As individuals age, the risk of developing conditions such as herniated discs escalates, leading to a heightened demand for effective treatment options. According to recent data, approximately 80 percent of adults experience back pain at some point in their lives, which underscores the urgency for innovative solutions in the Slip Disc Market. This trend is further exacerbated by sedentary lifestyles and poor ergonomics, which contribute to spinal issues. Consequently, healthcare providers are focusing on advanced treatment modalities, including minimally invasive surgeries and rehabilitation programs, to address these challenges. The growing awareness of the importance of spinal health is likely to propel the market forward, as patients seek timely interventions to alleviate pain and improve quality of life.

    Growing Demand for Non-Invasive Treatments

    The increasing preference for non-invasive treatment options is shaping the dynamics of the Slip Disc Market. Patients are increasingly seeking alternatives to traditional surgical interventions, which often involve longer recovery periods and higher risks. Non-invasive therapies, such as physical therapy, chiropractic care, and acupuncture, are gaining traction as effective methods for managing slip disc symptoms. Market data suggests that the non-invasive segment is expected to witness substantial growth, driven by patient demand for safer and less invasive solutions. Additionally, the rise of telehealth services has made it easier for patients to access these treatments from the comfort of their homes. This shift towards non-invasive approaches not only aligns with patient preferences but also reduces the overall healthcare burden, making it a pivotal factor in the ongoing evolution of the Slip Disc Market.

    Rising Awareness and Education on Spinal Health

    The growing awareness and education surrounding spinal health are crucial factors influencing the Slip Disc Market. Public health campaigns and educational initiatives aimed at promoting spinal health have led to increased recognition of the importance of early diagnosis and treatment of slip disc conditions. As individuals become more informed about the risks associated with poor spinal health, they are more likely to seek medical advice and intervention. This heightened awareness is reflected in the rising number of consultations and treatments for slip disc issues. Additionally, healthcare providers are increasingly emphasizing preventive measures, such as ergonomic assessments and lifestyle modifications, to mitigate the risk of developing spinal disorders. The ongoing efforts to educate the public about spinal health are likely to foster a proactive approach to treatment, thereby driving demand within the Slip Disc Market.

    Market Segment Insights

    Slip Disc Treatment Insights

    The market offers treatments to patients in the form of surgeries, therapies, as well as, proper medication, based on the condition of the problem.

    Slip Disc Diagnosis Insights

    The diagnosis of the slip disc problem among the patients is done based on imaging tests, conduction of nerve-related tests, as well as, physical examination.

    Slip Disc Type Insights

    The market segment of type includes cervical herniated discs, thoracic herniated, as well as, lumbar herniated disc tests of the patients suffering from slip disc issues.

    Get more detailed insights about Slip Disc Market Research Report- Global Forecast till 2035

    Regional Insights

    North America : Leading Innovation and Demand

    North America is the largest market for slip disc treatments, accounting for approximately 45% of the global market share. The region's growth is driven by advanced healthcare infrastructure, increasing prevalence of spinal disorders, and a rising aging population. Regulatory support from agencies like the FDA facilitates the introduction of innovative treatment options, enhancing patient access and outcomes. The United States is the primary contributor, with key players such as Medtronic, Johnson & Johnson, and Stryker leading the competitive landscape. The presence of established healthcare systems and significant investment in research and development further solidifies North America's position. The market is characterized by continuous innovation and a focus on minimally invasive procedures, catering to the growing demand for effective treatment solutions.

    Europe : Emerging Market with Growth Potential

    Europe is the second-largest market for slip disc treatments, holding around 30% of the global market share. The region's growth is propelled by increasing awareness of spinal health, advancements in medical technology, and supportive regulatory frameworks. The European Medicines Agency (EMA) plays a crucial role in ensuring the safety and efficacy of new treatments, which boosts market confidence and adoption. Leading countries include Germany, France, and the UK, where healthcare systems are increasingly adopting innovative solutions. Key players like B. Braun Melsungen AG and Zimmer Biomet are expanding their presence through strategic partnerships and product launches. The competitive landscape is marked by a focus on research and development, with an emphasis on improving patient outcomes and reducing recovery times.

    Asia-Pacific : Rapidly Growing Healthcare Sector

    Asia-Pacific is witnessing rapid growth in the slip disc market, accounting for approximately 20% of the global share. The region's expansion is driven by increasing healthcare expenditure, a growing elderly population, and rising awareness of spinal health. Countries like China and India are investing heavily in healthcare infrastructure, which is expected to further boost market growth in the coming years. China is the largest market in the region, with significant contributions from local and international players. The competitive landscape is evolving, with companies like NuVasive and Orthofix Medical Inc. expanding their operations. The focus on affordable healthcare solutions and the adoption of advanced technologies are key trends shaping the market, making it a focal point for future investments.

    Middle East and Africa : Untapped Market with Potential

    The Middle East and Africa region represents a smaller segment of the slip disc market, holding about 5% of the global share. However, it is characterized by significant growth potential driven by increasing healthcare investments, rising awareness of spinal disorders, and improving access to medical facilities. Governments are prioritizing healthcare reforms, which are expected to enhance market dynamics in the coming years. Countries like South Africa and the UAE are leading the way in adopting advanced medical technologies. The competitive landscape is gradually evolving, with both local and international players seeking to establish a foothold. Key players are focusing on partnerships and collaborations to expand their reach, making this region an attractive market for future growth opportunities.

    Key Companies in the Slip Disc Market market include

    Industry Developments

      • The European market companies are increasing their expenditure to improvise healthcare facilities by collaborating with the research and development of new productions. Also, there is an emergence of new therapies positively affecting the market growth.
      • Researches are being conducted in collaboration with Cornell University (USA) where new treatment techniques are being developed for herniated disc issues treatment that helps in repairing issues like a flat tyre.
      • Also, the researchers predict that in response to the disc injuries, the default responses should be stopped that will help in better treatment of the slip disc issues. This is being widely adopted by skilled medical professionals.
      • The Bonati Spine Institute that is known as a leader for patented Bonati spine treatment procedures, recently, rolled out a study that surgical interventions are one of the best ways to treat particular back injuries.

    Intended Audience

      • Slip disc manufacturers, providers, and suppliers
      • Laboratories conducting medical research
      • Companies conducting research and development procedures
      • Potential investors of the slip disc market
      • Providers of market research and consultation services

    Future Outlook

    Slip Disc Market Future Outlook

    <p>The Slip Disc Market is projected to grow at an 8.05% CAGR from 2024 to 2035, driven by increasing prevalence of spinal disorders, advancements in treatment technologies, and rising healthcare expenditure.</p>

    New opportunities lie in:

    • <p>Development of minimally invasive surgical techniques for faster recovery.</p>
    • <p>Expansion of telehealth services for remote patient monitoring and consultations.</p>
    • <p>Investment in AI-driven diagnostic tools to enhance treatment accuracy.</p>

    <p>By 2035, the Slip Disc Market is expected to achieve substantial growth, reflecting evolving healthcare dynamics.</p>

    Market Segmentation

    Report Scope

    MARKET SIZE 20249.2(USD Billion)
    MARKET SIZE 20259.941(USD Billion)
    MARKET SIZE 203521.56(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR)8.05% (2024 - 2035)
    REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR2024
    Market Forecast Period2025 - 2035
    Historical Data2019 - 2024
    Market Forecast UnitsUSD Billion
    Key Companies ProfiledMarket analysis in progress
    Segments CoveredMarket segmentation analysis in progress
    Key Market OpportunitiesAdvancements in minimally invasive surgical techniques enhance treatment options in the Slip Disc Market.
    Key Market DynamicsRising demand for minimally invasive treatments drives innovation and competition in the slip disc market.
    Countries CoveredNorth America, Europe, APAC, South America, MEA

    FAQs

    1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
      1. | 1.1 EXECUTIVE SUMMARY
      2. | | 1.1.1 Market Overview
      3. | | 1.1.2 Key Findings
      4. | | 1.1.3 Market Segmentation
      5. | | 1.1.4 Competitive Landscape
      6. | | 1.1.5 Challenges and Opportunities
      7. | | 1.1.6 Future Outlook
    2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
      1. | 2.1 MARKET INTRODUCTION
      2. | | 2.1.1 Definition
      3. | | 2.1.2 Scope of the study
      4. | | | 2.1.2.1 Research Objective
      5. | | | 2.1.2.2 Assumption
      6. | | | 2.1.2.3 Limitations
      7. | 2.2 RESEARCH METHODOLOGY
      8. | | 2.2.1 Overview
      9. | | 2.2.2 Data Mining
      10. | | 2.2.3 Secondary Research
      11. | | 2.2.4 Primary Research
      12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
      13. | | | 2.2.4.2 Breakdown of Primary Respondents
      14. | | 2.2.5 Forecasting Model
      15. | | 2.2.6 Market Size Estimation
      16. | | | 2.2.6.1 Bottom-Up Approach
      17. | | | 2.2.6.2 Top-Down Approach
      18. | | 2.2.7 Data Triangulation
      19. | | 2.2.8 Validation
    3. SECTION III: QUALITATIVE ANALYSIS
      1. | 3.1 MARKET DYNAMICS
      2. | | 3.1.1 Overview
      3. | | 3.1.2 Drivers
      4. | | 3.1.3 Restraints
      5. | | 3.1.4 Opportunities
      6. | 3.2 MARKET FACTOR ANALYSIS
      7. | | 3.2.1 Value chain Analysis
      8. | | 3.2.2 Porter's Five Forces Analysis
      9. | | | 3.2.2.1 Bargaining Power of Suppliers
      10. | | | 3.2.2.2 Bargaining Power of Buyers
      11. | | | 3.2.2.3 Threat of New Entrants
      12. | | | 3.2.2.4 Threat of Substitutes
      13. | | | 3.2.2.5 Intensity of Rivalry
      14. | | 3.2.3 COVID-19 Impact Analysis
      15. | | | 3.2.3.1 Market Impact Analysis
      16. | | | 3.2.3.2 Regional Impact
      17. | | | 3.2.3.3 Opportunity and Threat Analysis
    4. SECTION IV: QUANTITATIVE ANALYSIS
      1. | 4.1 Healthcare, BY Treatment (USD Billion)
      2. | | 4.1.1 Surgeries
      3. | | 4.1.2 Therapies
      4. | | 4.1.3 Medications
      5. | 4.2 Healthcare, BY Diagnosis (USD Billion)
      6. | | 4.2.1 Imaging Tests
      7. | | 4.2.2 Nerve-related Tests
      8. | | 4.2.3 Physical Examination
      9. | 4.3 Healthcare, BY Type (USD Billion)
      10. | | 4.3.1 Cervical Herniated Discs
      11. | | 4.3.2 Thoracic Herniated Discs
      12. | | 4.3.3 Lumbar Herniated Discs
      13. | 4.4 Healthcare, BY Region (USD Billion)
      14. | | 4.4.1 North America
      15. | | | 4.4.1.1 US
      16. | | | 4.4.1.2 Canada
      17. | | 4.4.2 Europe
      18. | | | 4.4.2.1 Germany
      19. | | | 4.4.2.2 UK
      20. | | | 4.4.2.3 France
      21. | | | 4.4.2.4 Russia
      22. | | | 4.4.2.5 Italy
      23. | | | 4.4.2.6 Spain
      24. | | | 4.4.2.7 Rest of Europe
      25. | | 4.4.3 APAC
      26. | | | 4.4.3.1 China
      27. | | | 4.4.3.2 India
      28. | | | 4.4.3.3 Japan
      29. | | | 4.4.3.4 South Korea
      30. | | | 4.4.3.5 Malaysia
      31. | | | 4.4.3.6 Thailand
      32. | | | 4.4.3.7 Indonesia
      33. | | | 4.4.3.8 Rest of APAC
      34. | | 4.4.4 South America
      35. | | | 4.4.4.1 Brazil
      36. | | | 4.4.4.2 Mexico
      37. | | | 4.4.4.3 Argentina
      38. | | | 4.4.4.4 Rest of South America
      39. | | 4.4.5 MEA
      40. | | | 4.4.5.1 GCC Countries
      41. | | | 4.4.5.2 South Africa
      42. | | | 4.4.5.3 Rest of MEA
    5. SECTION V: COMPETITIVE ANALYSIS
      1. | 5.1 Competitive Landscape
      2. | | 5.1.1 Overview
      3. | | 5.1.2 Competitive Analysis
      4. | | 5.1.3 Market share Analysis
      5. | | 5.1.4 Major Growth Strategy in the Healthcare
      6. | | 5.1.5 Competitive Benchmarking
      7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      8. | | 5.1.7 Key developments and growth strategies
      9. | | | 5.1.7.1 New Product Launch/Service Deployment
      10. | | | 5.1.7.2 Merger & Acquisitions
      11. | | | 5.1.7.3 Joint Ventures
      12. | | 5.1.8 Major Players Financial Matrix
      13. | | | 5.1.8.1 Sales and Operating Income
      14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
      15. | 5.2 Company Profiles
      16. | | 5.2.1 Medtronic (US)
      17. | | | 5.2.1.1 Financial Overview
      18. | | | 5.2.1.2 Products Offered
      19. | | | 5.2.1.3 Key Developments
      20. | | | 5.2.1.4 SWOT Analysis
      21. | | | 5.2.1.5 Key Strategies
      22. | | 5.2.2 Johnson & Johnson (US)
      23. | | | 5.2.2.1 Financial Overview
      24. | | | 5.2.2.2 Products Offered
      25. | | | 5.2.2.3 Key Developments
      26. | | | 5.2.2.4 SWOT Analysis
      27. | | | 5.2.2.5 Key Strategies
      28. | | 5.2.3 Stryker (US)
      29. | | | 5.2.3.1 Financial Overview
      30. | | | 5.2.3.2 Products Offered
      31. | | | 5.2.3.3 Key Developments
      32. | | | 5.2.3.4 SWOT Analysis
      33. | | | 5.2.3.5 Key Strategies
      34. | | 5.2.4 NuVasive (US)
      35. | | | 5.2.4.1 Financial Overview
      36. | | | 5.2.4.2 Products Offered
      37. | | | 5.2.4.3 Key Developments
      38. | | | 5.2.4.4 SWOT Analysis
      39. | | | 5.2.4.5 Key Strategies
      40. | | 5.2.5 DePuy Synthes (US)
      41. | | | 5.2.5.1 Financial Overview
      42. | | | 5.2.5.2 Products Offered
      43. | | | 5.2.5.3 Key Developments
      44. | | | 5.2.5.4 SWOT Analysis
      45. | | | 5.2.5.5 Key Strategies
      46. | | 5.2.6 Globus Medical (US)
      47. | | | 5.2.6.1 Financial Overview
      48. | | | 5.2.6.2 Products Offered
      49. | | | 5.2.6.3 Key Developments
      50. | | | 5.2.6.4 SWOT Analysis
      51. | | | 5.2.6.5 Key Strategies
      52. | | 5.2.7 B. Braun Melsungen AG (DE)
      53. | | | 5.2.7.1 Financial Overview
      54. | | | 5.2.7.2 Products Offered
      55. | | | 5.2.7.3 Key Developments
      56. | | | 5.2.7.4 SWOT Analysis
      57. | | | 5.2.7.5 Key Strategies
      58. | | 5.2.8 Zimmer Biomet (US)
      59. | | | 5.2.8.1 Financial Overview
      60. | | | 5.2.8.2 Products Offered
      61. | | | 5.2.8.3 Key Developments
      62. | | | 5.2.8.4 SWOT Analysis
      63. | | | 5.2.8.5 Key Strategies
      64. | | 5.2.9 Orthofix Medical Inc. (US)
      65. | | | 5.2.9.1 Financial Overview
      66. | | | 5.2.9.2 Products Offered
      67. | | | 5.2.9.3 Key Developments
      68. | | | 5.2.9.4 SWOT Analysis
      69. | | | 5.2.9.5 Key Strategies
      70. | 5.3 Appendix
      71. | | 5.3.1 References
      72. | | 5.3.2 Related Reports
    6. LIST OF FIGURES
      1. | 6.1 MARKET SYNOPSIS
      2. | 6.2 NORTH AMERICA MARKET ANALYSIS
      3. | 6.3 US MARKET ANALYSIS BY TREATMENT
      4. | 6.4 US MARKET ANALYSIS BY DIAGNOSIS
      5. | 6.5 US MARKET ANALYSIS BY TYPE
      6. | 6.6 CANADA MARKET ANALYSIS BY TREATMENT
      7. | 6.7 CANADA MARKET ANALYSIS BY DIAGNOSIS
      8. | 6.8 CANADA MARKET ANALYSIS BY TYPE
      9. | 6.9 EUROPE MARKET ANALYSIS
      10. | 6.10 GERMANY MARKET ANALYSIS BY TREATMENT
      11. | 6.11 GERMANY MARKET ANALYSIS BY DIAGNOSIS
      12. | 6.12 GERMANY MARKET ANALYSIS BY TYPE
      13. | 6.13 UK MARKET ANALYSIS BY TREATMENT
      14. | 6.14 UK MARKET ANALYSIS BY DIAGNOSIS
      15. | 6.15 UK MARKET ANALYSIS BY TYPE
      16. | 6.16 FRANCE MARKET ANALYSIS BY TREATMENT
      17. | 6.17 FRANCE MARKET ANALYSIS BY DIAGNOSIS
      18. | 6.18 FRANCE MARKET ANALYSIS BY TYPE
      19. | 6.19 RUSSIA MARKET ANALYSIS BY TREATMENT
      20. | 6.20 RUSSIA MARKET ANALYSIS BY DIAGNOSIS
      21. | 6.21 RUSSIA MARKET ANALYSIS BY TYPE
      22. | 6.22 ITALY MARKET ANALYSIS BY TREATMENT
      23. | 6.23 ITALY MARKET ANALYSIS BY DIAGNOSIS
      24. | 6.24 ITALY MARKET ANALYSIS BY TYPE
      25. | 6.25 SPAIN MARKET ANALYSIS BY TREATMENT
      26. | 6.26 SPAIN MARKET ANALYSIS BY DIAGNOSIS
      27. | 6.27 SPAIN MARKET ANALYSIS BY TYPE
      28. | 6.28 REST OF EUROPE MARKET ANALYSIS BY TREATMENT
      29. | 6.29 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSIS
      30. | 6.30 REST OF EUROPE MARKET ANALYSIS BY TYPE
      31. | 6.31 APAC MARKET ANALYSIS
      32. | 6.32 CHINA MARKET ANALYSIS BY TREATMENT
      33. | 6.33 CHINA MARKET ANALYSIS BY DIAGNOSIS
      34. | 6.34 CHINA MARKET ANALYSIS BY TYPE
      35. | 6.35 INDIA MARKET ANALYSIS BY TREATMENT
      36. | 6.36 INDIA MARKET ANALYSIS BY DIAGNOSIS
      37. | 6.37 INDIA MARKET ANALYSIS BY TYPE
      38. | 6.38 JAPAN MARKET ANALYSIS BY TREATMENT
      39. | 6.39 JAPAN MARKET ANALYSIS BY DIAGNOSIS
      40. | 6.40 JAPAN MARKET ANALYSIS BY TYPE
      41. | 6.41 SOUTH KOREA MARKET ANALYSIS BY TREATMENT
      42. | 6.42 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS
      43. | 6.43 SOUTH KOREA MARKET ANALYSIS BY TYPE
      44. | 6.44 MALAYSIA MARKET ANALYSIS BY TREATMENT
      45. | 6.45 MALAYSIA MARKET ANALYSIS BY DIAGNOSIS
      46. | 6.46 MALAYSIA MARKET ANALYSIS BY TYPE
      47. | 6.47 THAILAND MARKET ANALYSIS BY TREATMENT
      48. | 6.48 THAILAND MARKET ANALYSIS BY DIAGNOSIS
      49. | 6.49 THAILAND MARKET ANALYSIS BY TYPE
      50. | 6.50 INDONESIA MARKET ANALYSIS BY TREATMENT
      51. | 6.51 INDONESIA MARKET ANALYSIS BY DIAGNOSIS
      52. | 6.52 INDONESIA MARKET ANALYSIS BY TYPE
      53. | 6.53 REST OF APAC MARKET ANALYSIS BY TREATMENT
      54. | 6.54 REST OF APAC MARKET ANALYSIS BY DIAGNOSIS
      55. | 6.55 REST OF APAC MARKET ANALYSIS BY TYPE
      56. | 6.56 SOUTH AMERICA MARKET ANALYSIS
      57. | 6.57 BRAZIL MARKET ANALYSIS BY TREATMENT
      58. | 6.58 BRAZIL MARKET ANALYSIS BY DIAGNOSIS
      59. | 6.59 BRAZIL MARKET ANALYSIS BY TYPE
      60. | 6.60 MEXICO MARKET ANALYSIS BY TREATMENT
      61. | 6.61 MEXICO MARKET ANALYSIS BY DIAGNOSIS
      62. | 6.62 MEXICO MARKET ANALYSIS BY TYPE
      63. | 6.63 ARGENTINA MARKET ANALYSIS BY TREATMENT
      64. | 6.64 ARGENTINA MARKET ANALYSIS BY DIAGNOSIS
      65. | 6.65 ARGENTINA MARKET ANALYSIS BY TYPE
      66. | 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT
      67. | 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSIS
      68. | 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
      69. | 6.69 MEA MARKET ANALYSIS
      70. | 6.70 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT
      71. | 6.71 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSIS
      72. | 6.72 GCC COUNTRIES MARKET ANALYSIS BY TYPE
      73. | 6.73 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT
      74. | 6.74 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSIS
      75. | 6.75 SOUTH AFRICA MARKET ANALYSIS BY TYPE
      76. | 6.76 REST OF MEA MARKET ANALYSIS BY TREATMENT
      77. | 6.77 REST OF MEA MARKET ANALYSIS BY DIAGNOSIS
      78. | 6.78 REST OF MEA MARKET ANALYSIS BY TYPE
      79. | 6.79 KEY BUYING CRITERIA OF HEALTHCARE
      80. | 6.80 RESEARCH PROCESS OF MRFR
      81. | 6.81 DRO ANALYSIS OF HEALTHCARE
      82. | 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE
      83. | 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
      84. | 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE
      85. | 6.85 HEALTHCARE, BY TREATMENT, 2024 (% SHARE)
      86. | 6.86 HEALTHCARE, BY TREATMENT, 2024 TO 2035 (USD Billion)
      87. | 6.87 HEALTHCARE, BY DIAGNOSIS, 2024 (% SHARE)
      88. | 6.88 HEALTHCARE, BY DIAGNOSIS, 2024 TO 2035 (USD Billion)
      89. | 6.89 HEALTHCARE, BY TYPE, 2024 (% SHARE)
      90. | 6.90 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
      91. | 6.91 BENCHMARKING OF MAJOR COMPETITORS
    7. LIST OF TABLES
      1. | 7.1 LIST OF ASSUMPTIONS
      2. | | 7.1.1
      3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      4. | | 7.2.1 BY TREATMENT, 2025-2035 (USD Billion)
      5. | | 7.2.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      6. | | 7.2.3 BY TYPE, 2025-2035 (USD Billion)
      7. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
      8. | | 7.3.1 BY TREATMENT, 2025-2035 (USD Billion)
      9. | | 7.3.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      10. | | 7.3.3 BY TYPE, 2025-2035 (USD Billion)
      11. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      12. | | 7.4.1 BY TREATMENT, 2025-2035 (USD Billion)
      13. | | 7.4.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      14. | | 7.4.3 BY TYPE, 2025-2035 (USD Billion)
      15. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      16. | | 7.5.1 BY TREATMENT, 2025-2035 (USD Billion)
      17. | | 7.5.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      18. | | 7.5.3 BY TYPE, 2025-2035 (USD Billion)
      19. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      20. | | 7.6.1 BY TREATMENT, 2025-2035 (USD Billion)
      21. | | 7.6.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      22. | | 7.6.3 BY TYPE, 2025-2035 (USD Billion)
      23. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      24. | | 7.7.1 BY TREATMENT, 2025-2035 (USD Billion)
      25. | | 7.7.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      26. | | 7.7.3 BY TYPE, 2025-2035 (USD Billion)
      27. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
      28. | | 7.8.1 BY TREATMENT, 2025-2035 (USD Billion)
      29. | | 7.8.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      30. | | 7.8.3 BY TYPE, 2025-2035 (USD Billion)
      31. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      32. | | 7.9.1 BY TREATMENT, 2025-2035 (USD Billion)
      33. | | 7.9.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      34. | | 7.9.3 BY TYPE, 2025-2035 (USD Billion)
      35. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      36. | | 7.10.1 BY TREATMENT, 2025-2035 (USD Billion)
      37. | | 7.10.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      38. | | 7.10.3 BY TYPE, 2025-2035 (USD Billion)
      39. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      40. | | 7.11.1 BY TREATMENT, 2025-2035 (USD Billion)
      41. | | 7.11.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      42. | | 7.11.3 BY TYPE, 2025-2035 (USD Billion)
      43. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      44. | | 7.12.1 BY TREATMENT, 2025-2035 (USD Billion)
      45. | | 7.12.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      46. | | 7.12.3 BY TYPE, 2025-2035 (USD Billion)
      47. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      48. | | 7.13.1 BY TREATMENT, 2025-2035 (USD Billion)
      49. | | 7.13.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      50. | | 7.13.3 BY TYPE, 2025-2035 (USD Billion)
      51. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
      52. | | 7.14.1 BY TREATMENT, 2025-2035 (USD Billion)
      53. | | 7.14.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      54. | | 7.14.3 BY TYPE, 2025-2035 (USD Billion)
      55. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
      56. | | 7.15.1 BY TREATMENT, 2025-2035 (USD Billion)
      57. | | 7.15.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      58. | | 7.15.3 BY TYPE, 2025-2035 (USD Billion)
      59. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      60. | | 7.16.1 BY TREATMENT, 2025-2035 (USD Billion)
      61. | | 7.16.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      62. | | 7.16.3 BY TYPE, 2025-2035 (USD Billion)
      63. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      64. | | 7.17.1 BY TREATMENT, 2025-2035 (USD Billion)
      65. | | 7.17.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      66. | | 7.17.3 BY TYPE, 2025-2035 (USD Billion)
      67. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      68. | | 7.18.1 BY TREATMENT, 2025-2035 (USD Billion)
      69. | | 7.18.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      70. | | 7.18.3 BY TYPE, 2025-2035 (USD Billion)
      71. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      72. | | 7.19.1 BY TREATMENT, 2025-2035 (USD Billion)
      73. | | 7.19.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      74. | | 7.19.3 BY TYPE, 2025-2035 (USD Billion)
      75. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      76. | | 7.20.1 BY TREATMENT, 2025-2035 (USD Billion)
      77. | | 7.20.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      78. | | 7.20.3 BY TYPE, 2025-2035 (USD Billion)
      79. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      80. | | 7.21.1 BY TREATMENT, 2025-2035 (USD Billion)
      81. | | 7.21.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      82. | | 7.21.3 BY TYPE, 2025-2035 (USD Billion)
      83. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      84. | | 7.22.1 BY TREATMENT, 2025-2035 (USD Billion)
      85. | | 7.22.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      86. | | 7.22.3 BY TYPE, 2025-2035 (USD Billion)
      87. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      88. | | 7.23.1 BY TREATMENT, 2025-2035 (USD Billion)
      89. | | 7.23.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      90. | | 7.23.3 BY TYPE, 2025-2035 (USD Billion)
      91. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      92. | | 7.24.1 BY TREATMENT, 2025-2035 (USD Billion)
      93. | | 7.24.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      94. | | 7.24.3 BY TYPE, 2025-2035 (USD Billion)
      95. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      96. | | 7.25.1 BY TREATMENT, 2025-2035 (USD Billion)
      97. | | 7.25.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      98. | | 7.25.3 BY TYPE, 2025-2035 (USD Billion)
      99. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      100. | | 7.26.1 BY TREATMENT, 2025-2035 (USD Billion)
      101. | | 7.26.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      102. | | 7.26.3 BY TYPE, 2025-2035 (USD Billion)
      103. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      104. | | 7.27.1 BY TREATMENT, 2025-2035 (USD Billion)
      105. | | 7.27.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      106. | | 7.27.3 BY TYPE, 2025-2035 (USD Billion)
      107. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      108. | | 7.28.1 BY TREATMENT, 2025-2035 (USD Billion)
      109. | | 7.28.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      110. | | 7.28.3 BY TYPE, 2025-2035 (USD Billion)
      111. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      112. | | 7.29.1 BY TREATMENT, 2025-2035 (USD Billion)
      113. | | 7.29.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      114. | | 7.29.3 BY TYPE, 2025-2035 (USD Billion)
      115. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      116. | | 7.30.1 BY TREATMENT, 2025-2035 (USD Billion)
      117. | | 7.30.2 BY DIAGNOSIS, 2025-2035 (USD Billion)
      118. | | 7.30.3 BY TYPE, 2025-2035 (USD Billion)
      119. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
      120. | | 7.31.1
      121. | 7.32 ACQUISITION/PARTNERSHIP
      122. | | 7.32.1

    Slip Disc Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization
    Direct Access to Analyst
    Deliverable Format
    Platform Access
    Discount on Next Purchase 10% 15% 15%
    Printable Versions